BUSINESS ACCOUNT
-
Access reports individually or via Subscription
-
Receive monthly invoices with payment via CSA or hard dollars
-
Analyst access
-
Free Trial Subscriptions
-
Team account with shared subscriptions
-
Advanced analytics to track research consumption and performance
Perrigo Co: 1 director bought
A director at Perrigo Co bought 7,513 shares at 43.480USD and the significance rating of the trade was 85/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...
With a more favourable environment, PERRIGO improves to Slightly Positive
PERRIGO (US), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date November 20, 2020, the closing price was USD 48.11 and its potential was estimated at USD 57.13.
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Chattem Inc - Strategy, SWOT and Corporate Finance Report
Summary Chattem Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Chattem Inc (Chattem), a subsidiary of Sanofi SA, is a consumer healthcare company based in the US. The company manufactures, markets and distributes branded consumer healthcare products, toiletries, proprietary drugs, fragrances and dietary supplements. It offers skin and hair care products suc...
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Vermilion Int'l Compass: Global Equity Strategy
Big-picture technicals offer a compelling outlook for equities -- in the long-run. Despite arguably stretched trends, especially in the U.S. and EM, one indicator in particular keeps us optimistic: monthly charts. What is likely the least-used timeframe, monthly charts (> 20 years) offer the most clarity. And what's clear right now is: (1) Europe is on the doorstep of breaking above secular resistance; (2) Japan is breaking out above secular resistance; (3) and EM already has. Speaking of EM, we view this as the place to be, or overweight, in 2018. The EM/EAFE's 20-year chart (below) reveals ...
Perrigo Co: 1 director bought
A director at Perrigo Co bought 7,513 shares at 43.480USD and the significance rating of the trade was 85/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Chattem Inc - Strategy, SWOT and Corporate Finance Report
Summary Chattem Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Chattem Inc (Chattem), a subsidiary of Sanofi SA, is a consumer healthcare company based in the US. The company manufactures, markets and distributes branded consumer healthcare products, toiletries, proprietary drugs, fragrances and dietary supplements. It offers skin and hair care products suc...
Bausch Health Companies Inc. - Strategy, SWOT and Corporate Finance Report
Summary Bausch Health Companies Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Bausch Health Companies Inc. (Bausch Health or 'the company') is a pharmaceutical company engaged in the development, manufacture and marketing of pharmaceutical products. The company markets a range of pharmaceutical products, medical devices and OTC products primarily in the a...
Perrigo Company plc: Key Facts and Statistics - H1 - 1 July 2017
CORPORATES ISSUER PROFILE 27 October 2017 TABLE OF CONTENTS Company overview 1 Business description 2 Management strategy 4 Financial highlights 5 Capital structure and debt maturity 7 Company management 9 Ownership structure 10 Subsidiaries 10 Peer group 13 Related websites and information
Perrigo Company plc: Update to Discussion of Key Credit Factors Following Revision of Outlook to Stable
CORPORATES CREDIT OPINION 30 June 2017 Update RATINGS Perrigo Company plc Domicile Ireland Long Term Rating Baa3 Type Senior Unsecured - Fgn Curr Outlook Stable Please see the ratings section at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date. Contacts Morris Borenstein 212-553-1409 AVP-Analyst [email protected] P
With a more favourable environment, PERRIGO improves to Slightly Positive
PERRIGO (US), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date November 20, 2020, the closing price was USD 48.11 and its potential was estimated at USD 57.13.
Ford Equity US Rating and Forecast Report
Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.